RxDoctor Payments Data

Tatyana Tools

Adult Health · West End, NCNPI 1073746103

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 27.2% of the total. Among adult health clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,183in general payments, 2019–2025

Across 249 payments — averaging $28.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$2K
  • Sanofi$581
  • GSK$539
  • Novartis$471
  • Johnson & Johnson$463
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$7,163100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,183 in reported general payments places this provider in the 90th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,465
Medicare patients
212
Services billed
5,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab44$353,624
RinvoqUpadacitinib14$89,817
Cosentyx Sensoready (2 Pens)Secukinumab12$86,953
Yuflyma(Cf) (2 Pack)Adalimumab-Aaty11$72,711
Hydroxychloroquine Sulfate193$8,325
MethotrexateMethotrexate Sodium158$3,958
Mycophenolate Mofetil17$1,508
Leflunomide22$1,423
Prednisone177$1,026
Alendronate Sodium20$240
Folic Acid22$188
Allopurinol29$169
Meloxicam14$54
Tramadol Hcl11$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,956$89,81714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 adult health providers in North Carolina.

Other adult health in West End

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →